

**Introduction:** Hypertension is a major risk factor for premature death, cardiovascular disease, and stroke worldwide. However, due to the chronic nature of hypertension, patients are at an increased risk of developing mental and emotional disorders, which can affect their adherence to self-care.

**Objectives:** To conduct a systematic review to investigate the psychological profile, psychological characteristics, and personality traits of hypertensive patients and their role in self-care adherence.

**Methods:** A thorough and comprehensive literature search was conducted to identify relevant studies for this review. PubMed, Scopus, and APA PsycInfo databases were searched from their inception until March 7th, 2023. The protocol for this review will be registered in the International Prospective Register of Systematic Review (PROSPERO) in the future.

**Results:** After applying inclusion and exclusion criteria and removing duplicate results, 55 articles were selected, the majority of which were grouped into three main categories based on psychological profiles for accurate analysis and comparison.

**Conclusions:** This systematic review contributes to the investigation of the relationship between psychological profiles and self-care in hypertensive patients. Despite the prevailing controversy in the literature, a greater proportion of studies indicate that depression, anxiety, low quality of life, type D personality and neurotic personality have a negative impact on self-care in hypertension.

**Disclosure of Interest:** None Declared

## EPV0290

### Neuropsychiatric Manifestations of Tuberous Sclerosis in a young adult male in a Psychiatry Hospital in Botswana: a case report

W. T. Chabalala<sup>1,2\*</sup>, K. Bojosi<sup>1,2</sup>, T. Maphane<sup>1,2</sup> and A. Olashore<sup>1,2</sup>

<sup>1</sup>Department of Psychiatry, University of Botswana and <sup>2</sup>Department of Psychiatry, Sbrana Psychiatry Hospital, Gaborone, Botswana

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.1027

**Introduction:** Tuberous sclerosis complex (TSC) is a disorder that affects multiple systems and was first described in 1880. Its symptoms include seizures, intellectual disability, and adenoma sebaceum. TSC is caused by mutations in the TSC1 and TSC2 genes and is inherited in an autosomal dominant manner.

**Objectives:** This report highlights a case of a patient with an unusual psychological presentation evaluated in a psychiatric hospital.

**Methods:** The patient presented with psychotic features and abnormal behavior. A physical examination showed neurocutaneous lesions. After assessment a diagnosis of Tuberous sclerosis complex was confirmed through MRI Brain and genetic testing. Some of his relatives also showed similar neuropsychiatric symptoms.

**Results:** Tuberous sclerosis complex is diagnosed based on TSC Clinical Consensus Group guidelines of 2012. Our patient fulfilled 4 of the major criteria and genetic testing also yielded a pathogenic variant. A TAND checklist (TSC-Associated Neuropsychiatric Disorders) is used to guide clinicians on areas to prioritize when managing TSC patients.

Image:





Image 2:



Image 3:



**Conclusions:** Given that psychiatry may be the first contact for TSC patients, especially in low-resource settings. Patients referred to psychiatry, therefore, need to be thoroughly examined to exclude neuropsychiatric disorders, and a multidisciplinary team approach is vital in investigating and managing these cases.

**Disclosure of Interest:** None Declared

## EPV0292

### Elevated Soluble ST2 Blood Levels in Patients with Depression and Comorbid Heart Failure: A Correlative Study

A. K. Sikora\* and S. Fedorov

Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.1028

**Introduction:** Depressive disorders frequently coexist with chronic medical conditions like heart failure (HF), significantly impacting patients' overall health and quality of life. This study aims to explore the correlation between soluble ST2 molecule levels and the presence of depressive disorders in patients with heart failure.

**Objectives:** A total of 200 patients, all diagnosed with heart failure, were included in this study. Among them, 30 patients were mentally healthy, and the remaining 170 exhibited medium-level depressive disorders. Blood samples were collected and analyzed for soluble ST2 levels to assess the potential correlation between depressive disorders and soluble ST2 levels in patients with heart failure.

**Methods:** A total of 200 patients, all diagnosed with heart failure, were included in this study. Among them, 30 patients were mentally healthy, and the remaining 170 exhibited medium-level depressive disorders. Blood samples were collected and analyzed for soluble ST2 levels to assess the potential correlation between depressive disorders and soluble ST2 levels in patients with heart failure.

**Results:** The study demonstrated a statistically significant finding, indicating that the levels of soluble ST2 were 1.6 times higher in patients with depression and comorbid heart failure compared to mentally healthy individuals with heart failure.

**Conclusions:** This study elucidates a statistically significant correlation between medium-level depressive disorders and elevated soluble ST2 levels in patients with coexisting heart failure, shedding light on the potential role of soluble ST2 as a biomarker in identifying and managing depressive disorders in heart failure patients. The observed 1.6-fold increase in soluble ST2 levels in heart failure patients with depression emphasizes the importance of mental health assessment and intervention in individuals with chronic medical conditions, particularly heart failure, to enhance overall care and outcomes.

**Disclosure of Interest:** None Declared

## EPV0293

### Intractable Singultus: Causes, diagnosis and treatment. A case report

C. Díaz Mayoral<sup>1\*</sup>, E. Arroyo Sánchez<sup>1</sup>, A. Martínez Pillado<sup>2</sup> and P. Setién Preciados<sup>1</sup>

<sup>1</sup>Psiquiatría, Hospital Universitario Príncipe de Asturias and

<sup>2</sup>Psiquiatría, Hospital Universitario Rey Juan Carlos, Madrid, Spain

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.1029

**Introduction:** Hiccups are involuntary, spasmodic contractions of the diaphragm and intercostal muscles that cause inspiration and are interrupted by closure of the glottis. Most sources define the term "persistent hiccups" as lasting more than 2 days and "intractable" as lasting more than 1 month. Both are most likely associated with a pathologic process. "Intractable hiccups" should lead to investigation of organic pathology. If it does not improve, it can interfere with the patient's ability to eat, socialize and sleep, leading to a significant worsening of quality of life. "Intractable hiccups" are more frequent in men (91%), over 50 years of age. Women suffer from psychogenic hiccups more frequently than men. Anxiety or stress can trigger hiccups. Multiple neurotransmitters are involved.

**Objectives:** We present a theoretical review on the topic.

**Methods:** A bibliographic review on the topic.

**Results:** In recent years, new trials and case series have been published, and regulatory agencies have issued new recommendations on the use of pharmacologic agents for this indication. The literature has described the efficacy of several pharmacologic agents in the empiric treatment of persistent and intractable hiccups. Most of these target dopaminergic and GABAergic receptors.

Based on limited efficacy and safety data, Baclofen and Gabapentin can be considered as first-line treatment for intractable and persistent hiccups, as they suggest efficacy and are less likely to cause long-term side effects than standard neuroleptic agents. Dopamine blocking agents such as Metoclopramide, Chlorpromazine, and Haloperidol, could be used as second line. In one study, withdrawal of Benzodiazepines or addition of Pregabalin was found to help reduce hiccups.

The patient we consulted came for persistent hiccups or singultus of 2 years of evolution. Organic pathology was ruled out. She related the onset of the symptoms to different stressors that had caused her anxiety. We administered Escitalopram and Gabapentin and indicated withdrawal of Bromazepam, which she started taking months ago. In follow-up appointments she reported a decrease in the intensity and frequency of the symptoms, with a notable improvement in her quality of life.

**Conclusions:** Considering all available evidence, a treatment algorithm with Baclofen is recommended as first-line therapy for persistent and intractable hiccups. Gabapentin may also be safe and effective in the long-term treatment of this condition, especially for patients with CNS disease. Metoclopramide is no longer recommended for long-term treatment of hiccups. Clinical experience also supports the use of Chlorpromazine and other neuroleptics for acute, but not long-term, treatment. Going forward, large multicenter studies will be needed to create an adequate evidence base for the treatment of persistent and intractable hiccups. Until then, guidelines will continue to be based on unreliable data and clinical experience.

**Disclosure of Interest:** None Declared